Search the Newsreel

TCBK|Trico Bancshares|Price:57.900|Chg%:-0.010

This article provides a comprehensive stock analysis of Trico Bancshares (TCBK), highlighting its strong fundamentals, high growth potential, and relatively fair valuation. It notes high institutional ownership and recent "Hold" ratings from analysts, with expectations for an upward trend in the medium term. The …

SummitTX Capital L.P. Takes Position in Americold Realty Trust Inc. $COLD

SummitTX Capital L.P. has initiated a new position in Americold Realty Trust Inc. (NYSE:COLD) by purchasing 92,950 shares valued at approximately $1.07 million. Institutional investors now own 98.14% of the company, and analyst sentiment is mixed with a consensus "Hold" rating. Americold Realty Trust …

Capricor Therapeutics: FDA Advisory Panel Votes 9-3 That Evidence Does Not Support Deramiocel for DMD Cardiomyopathy

An FDA advisory committee voted 9-3 that the available evidence does not support the effectiveness of Deramiocel for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. While this recommendation is non-binding, the FDA will consider it as part of the Biologics License Application (BLA) review, with the …

Crédit Agricole S.A. legt Ergebnisse für das zweite Quartal und das erste Halbjahr bis zum 30. Juni 2026 vor

Crédit Agricole S.A. communique ses objectifs de résultats pour 2028

Price Action: LIC Housing Finance, Data Patterns down 3% post earnings; Pricol gains 4%

Stock Alert: RailTel Corp, Pricol, Filatex India, Mazagon Dock, LIC Housing Finance

Capricorn Energy Confirms Share Capital and Voting Rights Update

CREDIT AGRICOLE SA: STRONG ACTIVITY, ACCELERATING THE AI TRANSFORMATION

CREDIT AGRICOLE SA STRONG ACTIVITY, ACCELERATING THE AI TRANSFORMATION CRÉDIT AGRICOLE S.A. CRÉDIT AGRICOLE GROUP In m€ Q2 2026 Var. Q2/Q2 Q2 2026 Var.Q2/Q2 Revenues 7,363 +7.7% 10,880 +12.9% Expenses -3,870 +4.6% -6,143 +4.6% Gross Operating Income 3,493 +11.4% 4,737 +25.8% Cost of risk …

Pricol shares surge over 3% after Q1 profit jumps 34% YoY to Rs 67 crore, revenue climbs 23.5%

Levi & Korsinsky Announces Investigation of Securities Claims Against Capricor Therapeutics, Inc. (CAPR)

Levi & Korsinsky has launched an investigation into Capricor Therapeutics, Inc. (CAPR) following a significant stock drop. The drop occurred after FDA briefing documents raised concerns about the cardiac efficacy of Deramiocel and revealed a change in the statistical analysis plan. The firm is …

Americold faces $305M-$320M impairment charge, stock drops 7.8% amid fraud investigation.

Americold Realty Trust announced a non-cash impairment charge ranging from $305 million to $320 million due to the discontinuation of operations at its automated retail centers, following the termination of a deal with ADUSA Distribution. This news caused Americold's stock to fall by 7.84%. …

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for Duchenne muscular dystrophy cardiomyopathy, with 9 votes against and 3 for. Despite the non-binding negative vote on a narrow …

Capricorn Energy PLC Revenue Breakdown – LSE:CNE

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

ATLANTA, July 30, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STATNews reported that: “The Food and Drug Administration said Monday that Capricor …

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

Hagens Berman has opened an investigation into Capricor Therapeutics (NASDAQ: CAPR) following a significant stock crash after the FDA questioned the company's claims regarding its Duchenne muscular dystrophy drug. The FDA's briefing document revealed discrepancies between Capricor's characterization of its Phase 3 HOPE-3 trial …

Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (“Capricor” or the “Company”) for potential violations of the federal securities laws. On July 27, …

Capricor stock downgraded at Oppenheimer (CAPR:NASDAQ)

Oppenheimer downgraded Capricor Therapeutics (CAPR) after an FDA advisory committee voted against endorsing its lead drug, Deramiocel. This news caused Capricor's stock to drop over 45%, reaching a new 52-week low.

Marico profit plunges after four years

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy

Capricor Therapeutics' stock fell sharply after an FDA advisory panel overwhelmingly rejected the sufficiency of evidence supporting its Duchenne muscular dystrophy cell therapy, Deramiocel. The panel's decision echoed FDA staff concerns regarding post hoc changes to key analyses after the late-stage trial. This rejection …

Duchenne Therapy Has Aug. 22 FDA Action Target After Panel Vote

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against the effectiveness of Deramiocel for cardiomyopathy in Duchenne muscular dystrophy (DMD). This non-binding vote focused on a narrower indication than proposed, with the company noting supportive discussion on …

FDA Panel Says "No" To Capricor's DMD Drug Deramiocel, Citing "Fragile" Data; Shares Plunge

(RTTNews) - Shares of Capricor Therapeutics, Inc. (CAPR) have been hit hard this week following adverse regulatory developments related to Deramiocel, the company's investigational cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy. Duchenne muscular dystrophy (DMD) is a devastating genetic disorder characterized by progressive weakness …

Trico Bancshares (TCBK) Institutional Confidence

This article analyzes the institutional confidence score for Trico Bancshares (TCBK), which currently stands at 7.00, placing it 70th in the Banking Services industry. Institutional shareholding has increased to 78.15%, with James Simons being a major individual holder. The article also lists the top …

Americold Realty Trust (COLD) Projected to Release Quarterly Earnings on Thursday

Americold Realty Trust (COLD) is slated to release its Q2 2026 earnings before market open on Thursday, August 6th. Analysts project a slight loss of $0.0006 per share on revenues of $613.5 million, with full-year EPS guidance set between $1.20 and $1.30. The company …

Public Employees Retirement System of Ohio Decreases Stake in Americold Realty Trust Inc. $COLD

The Public Employees Retirement System of Ohio reduced its holding in Americold Realty Trust Inc. by 14.4% in Q1, selling 69,250 shares and retaining 411,724 shares worth $4.7 million. Despite mixed analyst ratings, with a consensus "Hold" and a $15.25 price target, Americold exceeded …

Capricor Duchenne cell therapy voted down by FDA panel

An FDA advisory panel voted against Capricor Therapeutics' experimental cell therapy, deramiocel, for Duchenne muscular dystrophy-related cardiomyopathy, citing insufficient evidence of effectiveness. This decision follows a contentious regulatory process and skepticism from FDA scientists regarding Capricor's data analysis. The FDA is expected to make …

TriCo Bancshares Q2 2026 Earnings: EPS Slightly Beats Estimates, Stock Edges Lower - Dividend Earnings Report

UBS Remains a Buy on Capricorn Metals Ltd (CMM)

TriCo (TCBK) Could Be a Great Choice

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Capricor and would like to discuss your legal rights, contact Bragar Eagel …

FDA panel votes against Capricor's Duchenne heart disease therapy

A U.S. FDA advisory panel voted against the effectiveness data for Capricor Therapeutics' experimental cell therapy, deramiocel, intended for a heart condition associated with Duchenne muscular dystrophy. The nine-to-three vote mirrored FDA staff concerns regarding insufficient evidence of efficacy and questioned changes in key …

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 clinical trial for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The study demonstrated a significant 54% slowing of upper limb function decline and clinically meaningful cardiac …

TriCo Bancshares (TCBK) outlines integration and proxy plans for First Hawaiian merger

TriCo Bancshares and First Hawaiian, Inc. are moving forward with their proposed merger, establishing Integration Management Offices in both banks to coordinate planning and communication. An internal email detailed the next steps, including open communication channels and team introductions. The companies also highlighted extensive …

Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

The FDA is holding advisory committee meetings for therapies from Capricor Therapeutics and Replimune, with briefing documents indicating potential challenges for approval. Meanwhile, Q2 earnings reports continue with GSK announcing a $2.5 billion cost-cutting plan and AstraZeneca affirming its 2030 revenue target of $80 …

Rush Island Management LP Acquires 168,657 Shares of Americold Realty Trust Inc. $COLD

Rush Island Management LP increased its stake in Americold Realty Trust Inc. (NYSE:COLD) by 5.8%, purchasing an additional 168,657 shares to bring its total holdings to 3.10 million shares, valued at approximately $35.5 million. Americold Realty Trust reported strong quarterly revenue and EPS, exceeding …

(COLD) Movement as an Input in Quant Signal Sets

This article analyzes Americold Realty Trust Inc. (NASDAQ: COLD), noting weak near and mid-term sentiment but a neutral long-term outlook. It identifies an exceptional 50:1 risk-reward setup targeting a 14.4% gain with minimal risk. The report provides AI-generated institutional trading strategies including position, momentum …